Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The accumulation of
p53 protein
in the nuclei of cancer cells is known to correlate well with the presence of mutations in the
p53
gene. We therefore investigated the immunohistochemical reactivity of the anti-
p53
antibody, PAb1801, in specimens taken from 149 cases of primary gastric cancer and processed by acetone fixation, in order to elucidate the incidence and clinicopathological significance of
p53
alterations in gastric cancer. Thirty-four out of 99 (34%) advanced gastric cancers and 11 out of 50 (22%) early gastric cancers showed positive reactions in the nuclei. The nuclei of non-cancerous cells, including gastric glandular epithelial cells, however, were not stained. Histopathologically, a nuclear accumulation of
p53 protein
was seen frequently in papillary adenocarcinoma, well- to moderately-differentiated tubular adenocarcinoma and poorly-differentiated adenocarcinoma with solid nests or focal tubular structures (43/101, 43%), but was rarely seen in signet-ring cell carcinoma, mucinous adenocarcinoma or poorly-differentiated adenocarcinoma growing in a scattered manner (2/48, 4%). There was no correlation between stainability of
p53 protein
and clinicopathological features such as depth of
tumor
invasion, microscopic lymphatic invasion, microscopic venous invasion, nodal involvement and clinicopathological stage in papillary adenocarcinoma, well- to moderately-differentiated tubular adenocarcinoma and poorly-differentiated adenocarcinoma with solid nests or focal tubular structures. The results suggest papillary adenocarcinoma, well- to moderately-differentiated tubular adenocarcinoma and poorly-differentiated adenocarcinoma with solid nests or focal tubular structures to share a common carcinogenetic pathway in which mutation of the
p53
gene has an important role to play at a relatively early stage. Additionally, we showed the applicability of immunohistochemical detection of
p53 protein
in endoscopic biopsy material routinely formalin-fixed. The current method may be of some help in routine practice in discriminating between normal, precancerous and cancer cells in the stomach.
...
PMID:High incidence of nuclear accumulation of p53 protein in gastric cancer. 127 44
The
p53
gene, located on chromosome 17p13.1, may be important in the pathogenesis of human neuroepithelial tumors, because it is a
tumor
suppressor gene and genetic alteration is essential for certain human cells to acquire the neoplastic phenotype. The structure and expression of the
p53
gene were investigated in cultured human glioma cells and biopsied specimens of neuroepithelial tumors. Immunocytochemical examination of
p53
gene expression revealed positive nuclear staining in six of seven glioma cell lines tested. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis demonstrated unequivocal heterogeneity of migration rate in
p53
bands. Pulse-chase analysis clearly showed an increased half-life of
p53
in cultured human glioma cells. These abnormalities are presumably due to genetic alterations in the
p53
gene. Nucleotide substitutions in exon 5, 7, or 8 of the
p53
gene could be detected by polymerase chain reaction-single strand conformational polymorphic analysis in four of seven (57%) human glioma cell lines, and nine of 29 (31%) biopsied specimens of neuroepithelial tumors examined. The present results indicate that genetic alterations in the
p53
gene are responsible for the tumorigenesis of at least some human neuroepithelial tumors.
...
PMID:Altered structure and expression of the p53 gene in human neuroepithelial tumors. 128 Jul 73
p53
was originally considered to be a nuclear oncogene, but several convergent lines of research have indicated that the wild-type gene functions as a
tumor
suppressor gene negatively regulating the cell cycle. Mutations in the
p53
gene have been detected in many
tumor
types and seem to be the most common genetic alterations in human cancer. In this preliminary study, sera of 92 patients (pts) with breast disease were analyzed for the presence of the mutant p53 protein (mp53) with a selective immunoenzyme assay employing a monoclonal antibody (PAb 240) specific for the majority of mammalian m
p53
but not for the wild-type protein. Of the 10 patients with benign breast disease, only two (20%) showed detectable m
p53
levels in the serum. In the breast cancer group, sera from 7 of the 30 pts (23%) without lymph node involvement were positive for m
p53
, as were 7 out of the 45 pts (15%) with metastatic lymph nodes and 1 out of the 7 pts (14%) with disseminated disease. The specificity of m
p53
assay evaluated in 20 healthy controls was 100%. These preliminary results showed that serum positivity for m
p53
is not related to breast disease extension. Further studies to assess the utility of m
p53
as a possible prognosis factor in breast cancer are currently in progress.
...
PMID:The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. 128 28
Carcinogenesis in human large intestine is a result of multiple, heterogeneous and random genetic changes. Deletion of
tumor
suppressor genes and activation of oncogenes appear to be important molecular events. These compromise the loss of chromosomes 5, 17, 18 or functional inactivation of FAP,
p53
and DCC genes. Activation of Ki-ras and c-myc oncogenes seems to be crucial for both cell immortalization and morphology modification. Identification of genes involved in this process enables both a screening and a new classification. Also it is an important step towards a gene therapy.
...
PMID:Colorectal carcinoma as a genetic phenomenon. 129 35
Nasopharyngeal carcinoma (NPC) is the third most common cancer in the southern provinces of China, but a rare cancer in other parts of the world. Epidemiological studies suggested a multifactorial etiology of NPC involving infection of Epstein Barr virus (EBV), genetic predisposition, environmental factors, such as consumption of salted fish, and other unknown factors.
p53
mutation is a common event in many forms of human cancers but its possible involvement in the pathogenesis of NPC has not been examined. The presence of
p53
mutation in NPC is studied by the sensitive PCR-SSCP analysis and direct DNA sequencing method. The frequent sites of
p53
mutation (exons 4 to 8) reported in other human tumors were studied. Thirty-eight biopsied tumors of NPC and 4 NPC cell lines were examined for the presence of
p53
mutation. No mutation of
p53
resulting in change in amino acid sequence of the encoded
p53 protein
was identified in any of the biopsies tumors. RFLP studies of the biopsied materials of NPC also revealed no loss of heterozygosity at chromosome region 17p13 in 15 out of 15 informative cases, which further supports the conclusion that
p53
mutation is an infrequent event in NPC. Apparently,
p53
mutation has no significant role in the pathogenesis of this special group of human cancers. However,
p53
mutation is frequently observed in cell lines derived from the primary NPC tumors. All the three NPC cell lines examined carry a missense
p53
mutation, suggesting that mutation of the
p53
gene may confer growth advantage to the
tumor
cells to become established in culture.
...
PMID:p53 mutation in human nasopharyngeal carcinomas. 129 43
Overexpression of
p53
-protein appears to be a common event in primary breast cancer. It has been proposed that the presence of elevated levels of this protein may be an independent prognostic factor and may be important for the ability of a
tumor
to metastasize. This study was performed to evaluate the influence of immunohistochemically detectable mutant p53-protein on metastasis-free survival of patients with breast cancer. Immunohistochemistry was performed on 117 paraffin-embedded biopsy specimens of consecutive patients with stage T1-T4 breast cancer, using a monoclonal antibody against
p53
suppressor gene product. 29 (24.8%) specimens showed positive staining, whereas in 88 (75.2%) a negative staining reaction for
p53
was found. Comparing time intervals to diagnosis of metastasis, using Kaplan-Meier curves, Log-Rank test revealed no significant differences in metastasis-free survival between
p53
positive and negative patients (P = 0.32), whereas statistically significant differences were noted for
tumor
stage (P < 0.01), nodal status (P < 0.01), histological grading (P < 0.01) and estrogen receptor status (P = 0.03). Mutant p53-protein, as detected by immunohistochemistry in paraffin embedded
tumor
tissue, does not appear to influence metastasis-free survival in patients with breast cancer.
...
PMID:Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. 129 80
The
p53
tumour suppressor gene is intensively studied because mutations in this gene are the most common genetic alteration so far identified in human cancer. Considerable emphasis has thus been placed on characterizing the biological differences between mutant and wild-type
p53 protein
. This has led to the realization that in cultured cells, mutant p53 behaves like an oncogene, whereas wild-type
p53
is a
tumor
suppressor gene. The
p53 protein
is also a target for the tumour virus oncogene products SV40 large T, adenovirus E1B, and human papillomavirus type 16 E6, which are all capable of forming complexes to the
p53 protein
. Although
p53
represents an extremely important cellular regulatory molecule which is well conserved, there exists two allelic variants of wild-type human
p53
that differ both in primary and confirmational structure. One variant contains an arginine at amino acid 72 (p53Arg), whereas the other form contains a proline at this residue (p53Pro). The possible implications for more than one allelic variant of wild-type human
p53
in the general population is unknown. The present study was undertaken to compare some of the biological features of the different wild-type
p53
variants. We present data demonstrating that there was a post-transcriptional selection against accumulation of both variants of wild-type human
p53
in 3T3-A31 cells, arguing that both forms are proliferation inhibitory in these cells. Both variants of human
p53
were stabilized by SV40 large T, but did not displace mouse
p53
from SV40 large T. Neither allelic variant of human
p53
was able to reduce significantly SV40-mediated anchorage-independent growth of 3T3-A31 cells.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Molecular analysis of different allelic variants of wild-type human p53. 129 28
We searched for possible mutations in the entire coding region of
tumor
suppressor gene
p53
in primary human renal cell carcinomas using polymerase chain reaction and single-strand conformational polymorphism analysis of RNA. We found
p53
mutations in 2 of 21 cases (10%). DNA sequencing of the polymerase chain reaction products verified that the first case included a 17-base deletion at the beginning of exon 6. The second case showed a T to C transition at nucleotide 1328 in exon 7. No clinical or pathological similarity was found in the renal cell carcinomas containing the mutated
p53
genes. Present results suggest that
p53
mutation is involved at low frequency in human renal cell carcinomas.
...
PMID:p53 gene mutation in primary human renal cell carcinoma. 129 77
p53
is a
tumor
suppressor gene that is mutated in diverse
tumor
types. Here we report the frequencies of common polymorphic variants at codon 72 of the
p53
gene in germline DNA of lung cancer cases and controls as determined by a polymerase chain reaction strategy. The observed allelic distribution was found to be significantly different between African-Americans and Caucasians in this U.S. population. The frequency of polymorphic variants was similar in lung cancer cases and controls after adjustment for race. However, among lung cancer patients the proline variant at codon 72 was in excess in adenocarcinoma patients by comparison with other histologies.
...
PMID:Allelic frequency of a p53 polymorphism in human lung cancer. 130 61
Multiple genome alterations can be seen within a
tumor
and continue to accumulate throughout development of the growth. Chromosome deletions occurring in tumors are generating much interest. To date, the best known model is retinoblastoma whose study gave rise to the concepts of anti-oncogene or
tumor
suppressor gene. Studies of genetic anomalies in colorectal tumors have led to an elegant model of colonic carcinogenesis in which multiple steps, each with its corresponding genetic anomaly, successively accumulate, with deletion of the
p53
gene occurring as a late event. Successive anomalies of the
p53
gene (mutations, deletions) occur during passage from a low-grade astrocytoma to a higher-grade astrocytoma. Studies of familial forms of breast cancer and of breast and ovarian cancer have also provided insight into the biology of these tumors, with the identification of a predisposing chromosomal area whose location is 17 q-12-21. These approaches open up possibilities for screening techniques and use of preventive treatments in highly selected patients. However they raise many ethical problems. There is a need for developing a charter for these family studies in the near future.
...
PMID:[Genetics and cancers]. 130 91
1
2
3
4
5
6
7
8
9
10
Next >>